
Last updated: 2026-09-22 20:29:00. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Bio-Rad Laboratories, Inc. (BIO.B) operates in the LABORATORY ANALYTICAL INSTRUMENTS sector and is listed on NYSE. The stock is currently priced at $390.54, with a market capitalization of $1.98B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $244.54 to $390.54. This page covers its latest market performance, valuation, price trends and company information.
$1.98B | |
$384.88 | |
$818.60 | |
$47.00 | |
-- | |
8.00 | |
423.00 | |
-- | |
$390.54 | |
$244.54 | |
-- | |
-- |
Bio-Rad Laboratories, Inc. (BIO.B) is trading at $342.37 in after-hours trading as of 2026-09-22 20:13:00, -- from the regular-session close of $0.00.
After-hours trading shows how investors are pricing BIO.B after the regular session closes. The current after-hours price is -- the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, Bio-Rad Laboratories, Inc. (BIO.B) moved from $290.00 to $390.54, representing a gain of 34.67% ($100.54).
The stock traded between $289.23 and $390.54 during the period. The latest price is near the upper end of the 7-day range, indicating strong upward.
The average daily volume was 232.74 shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 100.0%
BIO.B is currently trading at $390.54, placing it 100.0% of the way from its 52-week low of $244.54 to its 52-week high of $390.54. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
| Industry | LABORATORY ANALYTICAL INSTRUMENTS |
| Employees | 7450 |
| Exchange | NYSE |
| Company Website |
Eligible investors can buy real shares of Bio-Rad Laboratories, Inc. (BIO.B) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.